摘要
目的探讨Foxp3、CD3在非小细胞肺癌（NSCLC）组织中的表达及其与肺癌临床病理特征和预后的关系。方法选取62例NSCLC患者术后的肺癌组织标本（NSCLC组）及27例正常肺组织（距离肿块边缘5cm以上正常肺组织或另一叶肺组织）作为正常对照组。采用免疫组化方法分别检测两组组织中Foxp3、CD3表达的表达情况，并分析其与肺癌临床病理特征（年龄、性别、组织学类型、肿瘤大小、分化程度、pTNM分期、淋巴结转移与否）的关系。结果NSCLC组Foxp3、CD3阳性细胞数均显著多于正常对照组（P〈0．01）。两者显著相关（P〈001）。Foxp3阳性表达仅在不同分化程度间存在明显差异，低分化者Foxp3阳性细胞浸润量高于高、中分化者（P〈0．05）；CD3阳性表达仅在不同术后pTNM分期间存在明显差异，ⅢB期、Ⅳ期NSCLC组织中CD3阳性细胞数明显减少（P〈0.05）。Foxp3表达与患者术后生存时间无关（P〉0.05），CD3阳性细胞数与NSCLC患者术后生存时间呈线性正相关（P〈0．01），Foxp3阳性细胞数与CD3阳性细胞数比值（Foxp3／CD3）与患者生存时间呈线性负相关（P〈0.05）。pTNM分期、CD3阳性细胞绝对数有统计学意义，可作为NSCLC患者的独立预后因素。结论NSCLC组织中CD3阳性细胞数低、Foxp3／CD3大者T细胞肿瘤免疫作用抑制，影响患者术后生存时间。联合检测术后肺癌组织中Foxp3、CD3，并结合患者术后病理分期可以更好地评估NSCLC患者手术预后。
Objective To investigate the expression of Foxp3 and CD3 in non-small cell lung cancer （NSCLC） and its relation with clinical features and prognosis of the disease. Methods Expression of Foxp3 and CD3 was detected in cancer tissue samples of 62 patients of NSCLC and 27 samples of normal lung tissue by immunohistochemical staining. Results The number of Foxp3 masculine Treg cells and CD3 masculine T-lymphocytes in lung cancer tissue was more than that in normal tissue （P〈0.01）. The expression of Foxp3 was associated with CD3 （P〈0.01）. The number of Foxp3 masculine Treg cells was higher in poorly-differentiated tumor than in that in moderately-differentiated and well-differentiated tumor （ P〈0.05 ）. The number of CD3 masculine T-lymphocytes had remarkable differences in different stage of NSCLC and was diminished in stage III B and IV NSCLCs （ P〈0.05 ）. The number of CD3 masculine T-lymphocytes was positively correlated with survival time after surgery（P〈0. 01 ）; Foxp3 had no correlation （P 〉 0.05）; however the ratio of Foxp3 masculine/CD3 masculine T-lymphocytes was negatively correlated with survival time of patients （ P〈0.05 ）. COX proportional hazard model analysis showed that the stage of pTNM and the number of CD3 masculine T-lymphocytes were independent predictive factors for prognosis of NSCLC. Conclusion Detection of Foxp3 masculine Treg cells and CD3 masculine T-lymphocytes combined with pTNM staging can be of better value for prognosis of NSCLC patients after surgery.
出处
《浙江医学》
CAS
2010年第1期46-48,51,共4页
Zhejiang Medical Journal
